Newsroom

February 12, 2025

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

Read more
February 9, 2025

Hannah Storm's breast cancer diagnosis was a shock. Now the veteran sports journalist is helping others understand their risk

Read more
February 6, 2025

Hannah Storm breaks down latest with NBA trade deadline, Luka Doncic and more

Read more
February 3, 2025

Dallas Reed, MD, highlights trends and barriers in prenatal genetic testing

Read more
January 22, 2025

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Read more
December 16, 2024

NCCN Reinforces Prolaris' Value in Predicting Prostate Cancer Outcomes

Read more
November 14, 2024

There's a Nearly 100 Percent Accurate Baby Gender Predictor

Read more
November 10, 2024

Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence

Read more
September 25, 2024

Dr. Thaïs Aliabadi Is Hollywood’s Go-To OB/GYN

Read more
previous slide
    next slide

    Scientific publications

    See all

    High positive predictive value 22q11.2 microdeletion screening by prenatal cell-free DNA testing that incorporates fetal fraction amplification

    Read publication
    NPWH 2023

    Menopausal symptom management considerations in patients at high risk for breast cancer

    Read publication
    AUA Western 2023

    Active surveillance selection and durability in men with NCCN intermediate-risk, localized prostate cancer...

    SMFM 2024

    High positive predictive value of 22q11.2 microdeletion screening by prenatal cell-free DNA testing that...

    Read more
    ASCO 2024

    Improving a Polygenic Risk Score (PRS) for breast cancer (BC) risk assessment in diverse ancestries

    Read more
    previous slide
      next slide

      Press releases

      See all

      Jun 03, 2025

      Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

      Read more

      Jun 02, 2025

      Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

      Read more

      May 27, 2025

      Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

      Read more

      May 14, 2025

      Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

      Read more

      Public relations contacts

      Kate Schraml, Megan Manzari

      pr@myriad.com

      Investor relations contacts

      Matt Scalo

      ir@myriad.com
      X social media icon Linkedin social media icon

      About Myriad Genetics

      Myriad Genetics is a leader in genetic testing and precision medicine, providing insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease. 

      • Early insights helped Ashley prepare

        “Carrier screening empowers you to make the right decisions. Not only are you making a decision for yourself right now but you’re making a decision for the next 80, 90, 100 years to create a better life for you and your baby.”
        Watch Ashley's story

      • Prenatal screening gave Hannah time to plan

        “Once we got the noninvasive prenatal screening results back, we were able to meet with a lot more physicians.”

      • How Prolaris provided clarity for his prostate cancer treatment plan

        “Prolaris gave me the ability to maintain the lifestyle that my wife and I have lived with for many years now.”
        Watch Tim's story
      previous slide
        next slide